Recent Price Movement and Market Context
On 21 Nov 2025, Kopran’s stock touched an intraday low of Rs.129, representing a 3.73% decline during the trading session. The stock closed with a day change of -2.95%, underperforming the Pharmaceuticals & Biotechnology sector by 2.68%. This movement comes amid a broader market environment where the Sensex opened lower by 285.28 points and was trading at 85,344.16, down 0.34% for the day. Despite the Sensex being close to its 52-week high of 85,801.70 and trading above its 50-day and 200-day moving averages, Kopran’s share price has not followed the broader market’s relatively stable trend.
Technical Indicators Signal Weak Momentum
Kopran’s stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating sustained downward pressure. This technical positioning suggests that the stock has not found support at key levels over the short, medium, and long term. The 52-week high for Kopran was Rs.236.1, highlighting the extent of the decline over the past year.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Financial Performance Trends
Over the last year, Kopran’s stock has generated a return of -34.86%, contrasting with the Sensex’s positive return of 10.60% over the same period. The company’s financial results have reflected a challenging environment, with net sales declining by 22.2% in the most recent quarter ending September 2025. This marks the fifth consecutive quarter of negative results for the company, following a similar pattern in the previous year.
The company’s quarterly profit after tax (PAT) stood at a loss of Rs.9.92 crores, representing a fall of 234.4% compared to the corresponding period. Operating profit has shown a negative compound annual growth rate of 11.79% over the past five years, indicating subdued long-term growth. Return on capital employed (ROCE) for the half-year period was recorded at 5.38%, one of the lowest levels in recent years. Additionally, the operating profit to interest coverage ratio was at -2.53 times, signalling that operating earnings are insufficient to cover interest expenses.
Shareholding and Valuation Metrics
Despite Kopran’s market capitalisation, domestic mutual funds hold a minimal stake of just 0.01%, which may reflect a cautious stance towards the company’s current valuation and business outlook. The company’s average debt-to-equity ratio remains low at 0.23 times, suggesting limited leverage on the balance sheet.
Valuation metrics indicate that Kopran is trading at an enterprise value to capital employed ratio of 1.2, which is lower than the historical average for its peers in the Pharmaceuticals & Biotechnology sector. This discount in valuation corresponds with the company’s subdued profitability and recent financial performance. Over the past year, profits have declined by 66.7%, further impacting investor sentiment and valuation multiples.
Considering Kopran ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Comparative Performance and Sector Positioning
When compared to the broader BSE500 index, Kopran’s stock has underperformed over multiple time frames including the last three years, one year, and three months. This underperformance is notable given the Pharmaceuticals & Biotechnology sector’s general resilience and growth prospects. The stock’s 52-week low of Rs.129 is a reflection of this relative weakness and the company’s ongoing financial pressures.
Summary of Key Financial Indicators
To summarise, Kopran’s recent financial and market data reveal a company facing a challenging phase. The stock’s decline to Rs.129 marks a significant technical and psychological level, underscoring the impact of consecutive quarters of negative earnings and declining sales. While the company maintains a conservative debt profile, its profitability metrics and returns on capital employed remain subdued. The stock’s valuation discount relative to peers aligns with these fundamentals.
Investors and market participants will note that Kopran’s current position contrasts with the broader market’s positive momentum, as the Sensex trades near its 52-week high and maintains bullish moving averages. Kopran’s stock, however, continues to reflect the effects of its recent financial performance and sector-specific challenges.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
